Telix Pharmaceuticals (ASX:TLX) - Incoming CEO, Kevin Richardson
Incoming CEO, Kevin Richardson
Source: Twitter
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Telix Pharmaceuticals (TLX) appoints Kevin Richardson to the role of CEO Telix Americas
  • The senior global executive will step into the position from today, bringing with him 25 years of experience in the healthcare industry
  • Dr Christian Behrenbruch, Group CEO and Managing Director, says Kevin brings a new depth of sales and marketing experience to the company’s U.S. operations
  • Telix Pharmaceuticals ends the 0.37 per cent in the red to close at $5.45

Telix Pharmaceuticals (TLX) has appointed Kevin Richardson to the role of CEO Telix Americas.

The senior global executive will step into the position from today, bringing with him 25 years of experience in the healthcare industry and a proven track record in building and leading sales, marketing, and commercial teams.

“I look forward to bringing my experience in scaling up growth stage companies to ensure Telix is able to translate its strong start as a commercial-stage company into long-term success across the United States, Canada and South America,” the incoming CEO said of his appointment.

Mr Richardson most recently held the role of Chief Operating Officer of UroShape Medical, a technology company which developed and commercialised a medical device for a large, undertreatment segment in the women’s health market.

Prior to this, he spent seven years in America’s division of Sirtex Medical, which commercialised a device for the treatment of liver cancer where he oversaw a five-fold increase in sales for the US region.

Dr Christian Behrenbruch, Group CEO and Managing Director, said Kevin brings a new depth of sales and marketing experience to the company’s U.S. operations.

“His experience will be extremely valuable as we maximize the opportunity of our first commercial product and as we prepare to bring additional products to market,” Dr Christian Behrenbruch said.

“I have confidence that Kevin brings the leadership skills and track record that will drive our growth in the region.”

Telix Pharmaceuticals ended the 0.37 per cent in the red to close at $5.45.

TLX by the numbers
More From The Market Herald
MetalsGrove Mining (ASX:MGA) - Managing Director, Sean Sivasamy

" MetalsGrove Mining (ASX:MGA) begins soil sampling at Upper Coondina

MetalsGrove Mining (ASX:MGA) has begun a soil sampling program at its Upper Coondina lithium project in…
Bellavista Resources (ASX:BVR) - Non Executive Chairman, Mel Ashton

" Bellavista Resources (ASX:BVR) commissions second rig for Brumby, WA

Bellavista Resources (ASX:BVR) has commissioned a second rig to begin drilling at its Brumby zinc-silver-copper project…

" Sky Metals (ASX:SKY) encounters further tin mineralisation at Tallebung, NSW

Sky Metals (ASX:SKY) has reported further tin mineralisation at its Tallebung tin project in New South…
Spectur (ASX:SP3) - Managing Director, Gerard Dyson

" Spectur (ASX:SP3) raises $1.15m in SPP

Spectur (ASX:SP3) has raised $1.15 million through a security purchase plan (SPP) and shortfall offer.